Literature DB >> 29504721

Durvalumab in Stage III Non-Small-Cell Lung Cancer.

Matteo Santoni1,2, Nicola Battelli1, Sebastiano Buti3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29504721     DOI: 10.1056/NEJMc1716426

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.

Authors:  Yu Wang; Qingguo Sun; Ning Mu; Xiaoyang Sun; Yingying Wang; Songqing Fan; Ling Su; Xiangguo Liu
Journal:  Cell Commun Signal       Date:  2020-07-14       Impact factor: 5.712

2.  The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis.

Authors:  Xunge Lin; Jiaqi Liu; Meng Xu
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.